Essential elements for guiding patient segmentation in precision pharmacotherapy for rheumatoid arthritis: lessons up to 2025 [0.03%]
精准药物治疗类风湿关节炎患者分层指导的关键要素：截至2025年的经验教训
Koshiro Sonomoto,Yoshiya Tanaka
Koshiro Sonomoto
Introduction: Biological and targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs) have transformed rheumatoid arthritis (RA) management; however, individualizing treatment, balancing efficacy and safety r...
Povorcitinib for Hidradenitis suppurativa: a narrative review on clinical trial data with expert commentary [0.03%]
普沃西替尼治疗汗腺炎的临床试验数据叙述性综述及专家意见
Kenan Kherallah,Claire S Chung,Sharon Ontiveros et al.
Kenan Kherallah et al.
Introduction: Hidradenitis suppurativa (HS) is a chronic, inflammatory skin disorder with a heterogeneous pathophysiology that typically affects intertriginous regions and presents with recurrent tender nodules, abscesses...
Targeted treatment of anemia in myelofibrosis and the impact of JAK inhibitors [0.03%]
靶向治疗骨髓纤维化性贫血及JAK抑制剂的影响
Iman Al Noumani,Claire Harrison
Iman Al Noumani
Introduction: Anemia is a hallmark feature of Myelofibrosis (MF), frequently present at diagnosis and almost universal with disease evolution. It is a major contributor to symptom burden, transfusion dependence, healthcar...
Evaluating linaclotide for the treatment of functional constipation in children and adolescents [0.03%]
评估利那洛肽治疗儿童和青少年功能性便秘的疗效
Manuel Linares,Miguel Saps
Manuel Linares
Introduction: Pediatric functional constipation is a highly prevalent disorder associated with significant morbidity and impaired quality of life. Despite widespread use of osmotic and stimulant laxatives, a substantial p...
Targeted small molecules in polymyalgia rheumatica: the emerging role of JAK inhibitors beyond glucocorticoids and DMARDs [0.03%]
靶向小分子在多肌炎治疗中的作用：糖皮质激素和传统疾病修饰抗风湿药物之外的JAK抑制剂疗法的新角色
Miguel Ángel González-Gay,Miguel Álvarez-Rubio,Ana de Benito-Vernière et al.
Miguel Ángel González-Gay et al.
Introduction: Glucocorticoids remain the cornerstone of therapy for polymyalgia rheumatica (PMR), but their long-term use is associated with substantial toxicity. Glucocorticoid-sparing strategies, particularly anti-IL-6 ...
The impact of state-of-the-art pharmacotherapy for malaria in infants: a breakthrough? [0.03%]
婴幼儿革新型疟疾药物治疗的影响：突破吗？
Martin Peter Grobusch,Bayode Romeo Adegbite,Thomas Hanscheid et al.
Martin Peter Grobusch et al.
Pharmacotherapy options and drug development in bronchiectasis: spotlight on dipeptidyl-peptidase inhibitors [0.03%]
支气管扩张的药物治疗选择和新药开发：重点介绍二肽基肽酶抑制剂
Chiara Premuda,Andrea Gramegna,Sofia Misuraca et al.
Chiara Premuda et al.
Introduction: In recent years, the central role of inflammation in the development and persistence of the vicious vortex of bronchiectasis has become increasingly evident, gradually reshaping the therapeutic landscape. Hi...
Evaluating once-weekly insulin efsitora alfa for adults with type 2 diabetes [0.03%]
评估一项针对2型糖尿病成人患者的每周一次胰岛素efasitamab α治疗方案的效果
Akshaya Ramachandran,Jaskaran Batra,Cyrus Desouza
Akshaya Ramachandran
Introduction: This review summarizes current evidence on insulin efsitora alfa, a novel once-weekly basal insulin developed to simplify therapy in adults with diabetes. Its Fc-fusion molecular design enables a prolonged h...
Is bacterial lysate add-on therapy a cost-effective strategy for childhood asthma? Evidence from a Colombian economic model [0.03%]
哥伦比亚经济学模型证据：细菌溶胞产物附加疗法是儿童哮喘的成本效益策略吗？
Jefferson Antonio Buendía,Juan Antonio Buendia Sánchez
Jefferson Antonio Buendía
Introduction: Despite optimized standard therapy, many children with asthma continue to experience recurrent exacerbations. Bacterial lysates have demonstrated clinical benefits in reducing respiratory infections and asth...